Nova Agritech has received a license amendment from the Telangana Government that authorizes the company to manufacture biostimulants at its formulation plant. This regulatory approval marks an important milestone for the agricultural company as it expands its manufacturing capabilities.

License Amendment Details

The license amendment specifically enables Nova Agritech to produce biostimulants at its existing formulation plant facility. This approval from the Telangana Government provides the necessary regulatory framework for the company to enter the biostimulants manufacturing segment.

Product Range Expansion

The license amendment enables Nova Agritech to expand its product range by adding biostimulants to its manufacturing portfolio. This diversification allows the company to broaden its offerings in the agricultural inputs sector and potentially serve a wider customer base.

Biostimulants represent a growing segment in the agricultural industry, and this regulatory approval positions Nova Agritech to participate in this market. The company can now leverage its existing formulation plant infrastructure to manufacture these specialized agricultural products.

Manufacturing Capabilities

With the license amendment in place, Nova Agritech can utilize its formulation plant to produce biostimulants alongside its existing product lines. This development enhances the company's manufacturing flexibility and allows for better utilization of its production facilities.

The regulatory approval demonstrates Nova Agritech's compliance with government standards and requirements for biostimulants production, providing a foundation for the company's expansion into this product category.

Nova Agritech Limited has announced the resignation of Independent Director Mr. Kiran Kumar Adapa, effective January 12, 2026, due to professional commitments. The company has simultaneously reconstituted its Board committees to ensure continued governance compliance following the directorial change.

Director Resignation Details

Mr. Kiran Kumar Adapa (DIN: 09087754) submitted his resignation letter on January 12, 2026, stepping down from his position as Independent Director with immediate effect at 9:00 AM. The resignation was attributed solely to his other professional commitments, with the company confirming that no other material reasons contributed to his decision to leave.

Board Committee Reconstitution

Following the resignation, the Board convened an emergency meeting on January 12, 2026, from 3:00 PM to 3:50 PM to reconstitute various committees. The restructuring ensures all committees maintain the required composition and continue functioning effectively.

Audit Committee

The Audit Committee has been reconstituted with Mrs. Swapna Kandula replacing Mr. Kiran Kumar Adapa as a member:

Other Committee Changes

The Stakeholders Relationship Committee now includes Mr. Adabala Seshagiri Rao as a new member, with Mrs. Swapna Kandula serving as Chairman. The Nomination & Remuneration Committee has been similarly restructured with Mr. Ramesh Babu Nemani as Chairman, supported by Mrs. Swapna Kandula and Mr. Adabala Seshagiri Rao as members.

The Corporate Social Responsibility Committee maintains Mr. Kiran Kumar Atukuri as Chairman, with Mr. Ramesh Babu Nemani replacing the outgoing director as a member alongside Mr. Adabala Seshagiri Rao.

Additional Corporate Actions

The Board also resolved to dissolve the IPO Committee, citing the complete utilization of IPO proceeds as the reason for this decision. This dissolution reflects the company's successful deployment of funds raised through its public offering.

Regulatory Compliance

All changes have been implemented in accordance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has provided all required disclosures and documentation to stock exchanges, ensuring full regulatory compliance during this transition period.